Coating Comprising A Poly(Ethylene Glycol)-Poly(Lactide-Glycolide-Caprolactone) Interpenetrating Network

Abstract

Implantable medical devices are disclosed. The devices comprise a coating comprising an interpenetrating network or semi-interpenetrating network. The interpenetrating network or semi-interpenetrating network comprises poly(ethylene glycol) and an aliphatic polyester copolymer. A method of using the implantable device is also provided.

1 . An implantable medical device comprising a coating, the coating comprising an interpenetrating network (IPN) or semi-IPN, wherein the IPN or semi-IPN comprises poly(ethylene glycol) (PEG) and an aliphatic polyester copolymer. 
     
     
         2 . The implantable device of  claim 1 , wherein the aliphatic polyester copolymer comprises D,L-lactide or L-lactide. 
     
     
         3 . The implantable device of  claim 1 , wherein the aliphatic polyester copolymer comprises glycolide (GA). 
     
     
         4 . The implantable device of  claim 1 , wherein the aliphatic polyester copolymer comprises poly(lactide-co-glycolide-co-caprolactone) (PLGACL), poly(lactide-co-glycolide) (PLGA), or poly(butylene succinate). 
     
     
         5 . The implantable device of  claim 1 , wherein the IPN or semi-IPN comprises from about 1% to about 40% PEG by mass of the IPN or semi-IPN. 
     
     
         6 . The implantable device of  claim 1 , wherein the IPN or semi-IPN comprises from about 2% to about 25% PEG by mass of the IPN or semi-IPN. 
     
     
         7 . The implantable device of  claim 1 , wherein the IPN or semi-IPN comprises from about 2% to about 10% PEG by mass of the IPN or semi-IPN. 
     
     
         8 . The implantable device of  claim 1 , wherein the aliphatic polyester copolymer comprises lactide and glycolide in a molar ratio of lactide to glycolide ranging from about 50:50 to about 90:10. 
     
     
         9 . The implantable device of  claim 1 , wherein the aliphatic polyester copolymer comprises lactide and glycolide in a molar ratio of lactide to glycolide of about 75:25. 
     
     
         10 . The implantable device of  claim 1 , wherein coating further comprises a bioactive agent. 
     
     
         11 . The implantable device of  claim 1 , wherein coating further comprises a bioactive agent, and wherein the bioactive agent and the IPN or semi-IPN are in a weight ratio of the bioactive agent to the IPN or semi-IPN of about 1:1 to about 1:5. 
     
     
         12 . The implantable device of  claim 1 , wherein the coating further comprises a bioactive agent selected from the group consisting of paclitaxel, docetaxel, estradiol, 17-beta-estradiol, nitric oxide donors, super oxide dismutases, super oxide dismutases mimics, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), biolimus, tacrolimus, dexamethasone, dexamethasone acetate, rapamycin, rapamycin derivatives, 40-O-(2-hydroxy)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), zotarolimus, Biolimus A9 (Biosensors International, Singapore), AP23572 (Ariad Pharmaceuticals), γ-hiridun, clobetasol, pimecrolimus, imatinib mesylate, midostaurin, feno fibrate, prodrugs thereof, co-drugs thereof, and combinations thereof. 
     
     
         13 . The implantable device of  claim 1 , wherein the implantable device is a stent. 
     
     
         14 . A method, comprising implanting in a patient an implantable device according to  claim 1 .